Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vera Therapeutics Inc Cl A (NQ: VERA ) 47.34 +6.25 (+15.21%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,793,171 Open 49.90 Bid (Size) 45.55 (3) Ask (Size) 48.93 (8) Prev. Close 41.09 Today's Range 45.45 - 50.00 52wk Range 9.680 - 50.78 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years Today 10:33 EDT Vera Therapeutics announces ORIGIN Phase 2b trial data on atacicept, showing sustained IgAN improvement and kidney function stability over 96 weeks. Via Benzinga PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday Today 10:14 EDT Via Benzinga Performance YTD +203.27% +203.27% 1 Month +8.98% +8.98% 3 Month +32.12% +32.12% 6 Month +14.40% +14.40% 1 Year +337.93% +337.93% More News Read More Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug Today 10:13 EDT Via Investor's Business Daily Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 October 26, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 04, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 October 02, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases October 02, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 September 16, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN September 12, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 10, 2024 From Vera Therapeutics Via GlobeNewswire Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday September 03, 2024 Via Benzinga Vera Therapeutics to Participate at September Investor Conferences August 29, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From Vera Therapeutics Via GlobeNewswire VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024 August 08, 2024 Via InvestorPlace Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results August 08, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 05, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer July 01, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Appoints Christy J. Oliger to Board of Directors June 11, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 07, 2024 From Vera Therapeutics Via GlobeNewswire Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday June 03, 2024 Via Benzinga Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market May 31, 2024 Via Benzinga Topics Economy Exposures Interest Rates Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker May 29, 2024 Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) May 28, 2024 From Vera Therapeutics Via GlobeNewswire Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress May 25, 2024 From Vera Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
